Proliferation imaging to measure early cancer response to targeted therapy
- PMID: 19010830
- DOI: 10.1158/1078-0432.CCR-08-2233
Proliferation imaging to measure early cancer response to targeted therapy
Abstract
Positron emission tomography imaging using thymidine and analogues labeled with positron emitters provides noninvasive and quantitative estimates of regional cellular proliferation. This CCR Translations summary reviews the biological basis for proliferation imaging and discusses recent results using 18F-fluorothymidine-positron emission tomography to measure response to targeted therapy in the context of prior studies and potential future applications.
Comment on
-
[18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung.Clin Cancer Res. 2008 Nov 15;14(22):7423-9. doi: 10.1158/1078-0432.CCR-08-0312. Clin Cancer Res. 2008. PMID: 19010859
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
